Opinion Leaders in Dementia
·This board is to collect articles, research, educational events by opinion leaders in Dementia. It will look at this generally and only through publically…
Last updated 8 years ago
The clinical use of structural MRI in Alzheimer's Disease. February 2010. "Competing interests: N. C. Fox declares associations with the following companies: Abbott Laboratories, Elan Pharmaceuticals, Eisai, Eli Lilly, GE Healthcare, IXICO, Lundbeck, Pfizer, Sanofi-Aventis, Wyeth Pharmaceuticals"
Conflict of interest in psychiatry Psychiatric Bulletin (2005),29, 302-304 SYED AHMER, PRADEEP ARYA, DUNCAN ANDERSON AND RAFEY FARUQUI "The primary question this study raises is hovv valid and safe our evidence on treatment is considering the findings that almost three-quarters of RCTs had received some support from the manufacturer of the experimental drug, and that the outcomes of trials supported and not supported by manufacturer of the experimental drug were significantly different."
From: SIGN Guidelines Sent: 21 October 2013 RE: SIGN Guideline 86: Managernent of patients with dementia Dear Dr Gordon, In line with our records management policy, the Declarations of Interest are retained on record for three years after publication of the guideline and then destroyed. Since it is over 3 years since this guideline was published the Declarations have been destroyed. Best Wishes, SIGN Programme Lead
OmniaMed Update Thursday 7th November 2013 Edinburgh Dr Michael Serpell, Consultant and Senior Lecturer in Anaesthesia, Gartnaval General Hospital, Glasgow Professor Peter Connelly, Old Age Psychiatry Consultant, Murray Royal Hospital, Perth and co-Chair of the new Scottish Dementia Research Consortium Professor Emma Reynish, Consultant Geriatrician in NHS Fife and Professor in Dementia Research at the University of Stirling
SIGN 86, Management of patients with dementia: a national clinical guideline Published February 2006 Chaired by Dr Peter Connelly I have requested declarations of interest for all those on the "Guideline Development Group" - (requested 19 Oct 2013) as these are NOT published with this guideline
Predicting the outcome of cholinesterase inhibitor treatment in Alzheimer's disease P J Connely et al J Neurol Neurosurg Psychiatry 2005 76: 320-324 "There was no funding source or sponsor for this work. Competing interests: P J Connelly and N P Prentice have received honoraria and travel sponsorship from manufacturers of currently licensed cholinesterase inhibitors. P J Connelly and N P Prentice have received research funds from Eisai/Pfizer. K G Fowler has no competing interests."
This has just been submitted after my e-mail to Frank Jessen: Please note the COI statement in addition to my comment from the 20th of September Competing interests:Within the last three years: Consultation fees from Jansen-Cilag and Novartis, speaker fees from Novartis and Esai. Should the BMJ not be concerned about this?